Theriva Biologics, Inc. (TOVX)
NYSEAMERICAN: TOVX · Real-Time Price · USD
1.170
+0.070 (6.36%)
Apr 1, 2025, 9:30 AM EST - Market open
Theriva Biologics Employees
Theriva Biologics had 22 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
22
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,166,045
Market Cap
3.12M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
TOVX News
- 13 days ago - Theriva™ Biologics to Present at the 2025 NeauxCancer Conference - GlobeNewsWire
- 25 days ago - Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results - GlobeNewsWire
- 26 days ago - Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual - GlobeNewsWire
- 4 months ago - Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer - GlobeNewsWire
- 5 months ago - Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma - GlobeNewsWire
- 6 months ago - Theriva Biologics Announces Pricing of $2.5 Million Public Offering - GlobeNewsWire
- 6 months ago - Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer - GlobeNewsWire
- 7 months ago - Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government's National Knowledge Transfer Program - GlobeNewsWire